Epstein–Barr virus positive diffuse large B-cell lymphoma
Human medical condition / From Wikipedia, the free encyclopedia
Epstein–Barr virus positive diffuse large B-cell lymphoma, not otherwise specified (EBV+ DLBCL, NOS) is a form of diffuse large B-cell lymphomas (DLBCL) accounting for around 10-15% of DLBCL cases. DLBCL are lymphomas in which B-cell lymphocytes proliferate excessively, invade multiple tissues, and often causes life-threatening tissue damage. EBV+ DLBCL is distinguished from DLBCL in that virtually all the large B cells in the tissue, infiltrates of the Epstien-Barr virus (EBV) express EBV genes characteristic of the virus's latency III (common in the elderly) or II (common in younger patients) phase.[2] EBV is a ubiquitous virus, infecting around 95% of the world population.
Epstein–Barr virus positive diffuse large B-cell lymphoma | |
---|---|
Other names | EBV+ DLBCL, NOS |
Specialty | Hematology, oncology |
Symptoms | B symptoms |
Causes | Epstein-Barr virus infection |
Risk factors | Old age; immunosuppression |
Diagnostic method | Histology of involved tissue |
Treatment | Chemotherapy (R-CHOP) |
Medication | Rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone, etoposide, prednisolone |
Prognosis |
|
Frequency | 5-15% of DLBCL cases |
EBV+ DLBCL, NOS was previously named Epstein–Barr virus-positive DLBCL of the elderly, by the WHO in 2008; because it appeared to be limited to people over the age of 50.[3][4]: 369–370 [5] The name was changed to EBV+ DLBCL, NOS by the WHO in 2016, after the disease was described in much younger adults and children.[6][7] The disease is also classified as one of numerous related and interrelated Epstein-Barr virus-associated lymphoproliferative diseases.[6] EBV+ DLBCL, NOS is usually CD20 positive, and has clonal immunoglobulin gene rearrangement.[4]: 380